Enantioselective HPLC‐UV method for determination of eslicarbazepine acetate (BIA 2‐093) and its metabolites in human plasma

• DOI: 10.1002/bmc.858
• Publication Date: 2007-06-26T15:50:05Z
• Authors: Gilberto Alves; Isabel Figueiredo; Margarida Castel‐...; Ana Loureiro; Ana Fortuna; Amílcar Falcão; Margarida Caramona
• Keywords: Oxcarbazepine; Therapeutic Drug Monitoring

Abstract Eslicarbazepine acetate (BIA 2‐093) is a novel central nervous system drug undergoing clinical phase III trials for epilepsy and II bipolar disorder. A simple reliable chiral reversed‐phase HPLC‐UV method was developed validated the simultaneous determination of eslicarbazepine acetate, oxcarbazepine, S‐ licarbazepine R ‐licarbazepine in human plasma. The analytes internal standard were extracted from plasma by solid‐phase extraction using Waters Oasis ® HLB cartridges. Chromatographic separation achieved isocratic elution with water–methanol (88:12, v/v), at flow rate 0.7 mL/min, on LichroCART 250‐4 ChiraDex ( β ‐cyclodextrin, 5 µm) column 30°C. All compounds detected 225 nm. Calibration curves linear over range 0.4–8 µg/mL 0.4–80 each enantiomer. overall intra‐ interday precision accuracy did not exceed 15%. Mean relative recoveries varied 94.00 to 102.23% limit quantification assay 0.4 all compounds. This seems be useful tool research therapeutic monitoring its metabolites licarbazepine, oxcarbazepine. Copyright © 2007 John Wiley & Sons, Ltd.